Comparative Study of the Antiarrhythmic Activity of Liposomal Forms of Lappaconitine Hydrobromide and its Complex with Glycyrrhizic Acid Monoammonium Salt in the Aconitine Arrhythmia Model

Results of a comparative study of the antiarrhythmic activity of liposomal forms of lappaconitine hydrobromide (LH) and its complex with the monoammonium salt of glycyrrhizic acid (MASGA) in the aconitine arrhythmia model (pathognomonic for class I antiarrhythmic drugs according to the VaughnWilliams classification) and the antiarrhythmic drug Allapinin® (lappaconitine hydrobromide) are presented. The liposomal form of LH/MASGA with a LH concentration of 1 ìg/mL is shown to restore effectively the contractile activity of papillary muscle. Moreover, the restored contractile activity persists for a longer time without arrhythmia recurrence than is observed for Allapinin, where arrhythmia recurred after 90 min. It is assumed that the liposomal form of LH/MASGA may become a promising antiarrhythmic drug because of a marked decrease in the toxic effect and a pronounced trend toward a decrease in the time required to restore heart rhythm without arrhythmia recurrence.